Scilex Holding
14.09
Open
Market Cap
High
Low
Close
Volume
P/E Ratio
Div/Yield
About Scilex Holding
Founded in February 2019 in Delaware, Scilex Holding Company is an innovative revenue-driven enterprise dedicated to the acquisition, development, and commercialization of non-opioid therapeutic products for the treatment of acute and chronic pain. The company believes its pioneering portfolio of non-opioid medications holds the potential to deliver effective pain management solutions with transformative impacts on patients' lives. Targeting indications characterized by significant unmet needs and substantial market opportunities, Scilex is committed to advancing therapies that improve outcomes for patients suffering from both acute and chronic pain. For more information, visit http://www.scilexholding.com Company address: 960 San Antonio Road Palo Alto, CA 94303
Trade GPT
Similar Stocks
© Rockalpha Limited. All Rights Reserved.
Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.